Magdalena Murawska

Dr. Magdalena Murawska

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2013 in Medical Oncology
Verified
Journal Article
Open access
PDF file
KPKatarzyna Pogoda
Katarzyna Pogoda
ANAnna Niwińska
Anna Niwińska
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska
TPTadeusz Pieńkowski
Tadeusz Pieńkowski
The aim of the study was to assess the rate, pattern, and time of recurrence in patients with triple-negative breast cancer (TNBC) and to evaluate factors influencing recurrence and overall survival in this group of patients. Out of 2,534 consecutive breast cancer patients diagnosed between January 2005 and December 2006, 228 (9 %) were TNBC (ER/PR/HER2-negative). The clinicopathological characteristics were determined using descriptive statistics. The overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan–Meier method. The univariate and multivariate analyses were developed to identify factors influencing recurrence and survival in TNBC patients. After 6 years of observation, metastatic disease occurred in 35 % of all TNBC patients: 15 % in the brain, 14 % in the lungs, 11 % in the bones, 8 % in the liver, and 14 % had locoregional relapse. The highest risk of recurrence was during the first 3 years after primary treatment, and then, during the next 2 years of observation, it did not change. 6-year DFS and OS were 68 and 62 %, respectively. Factors influencing recurrence were tumor size and systemic adjuvant chemotherapy, while factors influencing overall survival were tumor size, nodal status, adjuvant/neoadjuvant treatment, and metastases in the brain, liver, and bones. Characteristic pattern of recurrence in time was revealed. The tumor size was responsible for recurrence despite lack of involvement of lymph nodes. Aggressive adjuvant/neoadjuvant treatment ordered in all clinical stages of TNBC (including N0) was factor responsible for avoiding local and distant relapse and prolonging overall survival.

20 February 2007 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
HRHalina Rudnicka
Halina Rudnicka
ANAnna Niwińska
Anna Niwińska
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska

16 January 2013 in Medical Oncology
Verified
Journal Article
Open access
PDF file
ANAnna Niwińska
Anna Niwińska
HRHalina Rudnicka
Halina Rudnicka
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska
The aim of the study was to define biological subtypes of breast cancer that have the propensity to metastasize to the leptomeninges and to assess factors influencing survival from detection of leptomeningeal metastatis (LM). One hundred and eighteen consecutive breast cancer patients with LM were treated in one institution, between the years 1999 and 2009; 40.5 % of patients had triple-negative subtype, 37.5 % had luminal A subtype and 22 % had HER2-positive subtypes (luminal B and HER2). Of patients with LM, 35 % had lobular cancer. Median survival from the detection of LM was 18 weeks, and 1-year survival was 16 %. Cox multivariate analysis revealed that performance status and systemic treatment statistically significantly influenced survival of patients with LM. Triple-negative biological subtype and lobular histological type of breast cancer had the propensity to metastasize to the leptomeninges. Performance status and systemic treatment ordered after detection of LM statistically significantly influenced survival.

1 January 2009 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
IRIwona K. Rzepecka
Iwona K. Rzepecka
ARAlina Rembiszewska
Alina Rembiszewska
AFAnna Felisiak
Anna Felisiak
IZIzabela Ziolkowska-Seta
Izabela Ziolkowska-Seta
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska
JKJolanta Kupryjańczyk
Jolanta Kupryjańczyk
PI3K/AKT signalling pathway controls important cellular processes such as the cell proliferation and apoptosis. PIK3CA gene encoding a catalytic subunit of the PI3K is mutated and/or amplified in v...

1 July 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ANAnna Niwińska
Anna Niwińska
MTMałgorzata Tacikowska
Małgorzata Tacikowska
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska

1 April 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ANAnna Niwińska
Anna Niwińska
Magdalena MurawskaMagdalena Murawska
Magdalena Murawska